Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (August 2026)
16 slides from Revive Therapeutics's investor presentation, August 2026
Slide 1: Biodefence & Pandemic Preparedness Therapeutics
Biodefence & Pandemic Preparedness Therapeutics CSE: RVV OTCQB: RVVTF FRANKFURT: 31R INVESTOR PRESENTATION · Q3 2026 82 Richmond Street East, Toronto, ON M5C 1P1 | 1-888-901-0036 | info@revivethera.com
Slide 2: Forward-Looking Statement
IMPORTANT NOTICE Forward-Looking Statement This presentation contains forward-looking information within the meaning of applicable Canadian securities legislation, including statements about Revive's strategy in biodefence and pandemic preparedness; the potential safety, efficacy, utility, governmen
Slide 3: Revive at a Glance
INVESTMENT SNAPSHOT Revive at a Glance One focus. Lead asset — bucillamine — aimed at one market: medical countermeasures (biodefence and pandemic preparedness) for governments and defence agencies. Positive data. In August 2026, DRDC reported that bucillamine matched N-acetylcysteine (NAC) on the m
Slide 4: One Focus.
COMPANY OVERVIEW One Focus. Lead asset — bucillamine — aimed at one market: medical countermeasures AT A GLANCE (biodefence and pandemic preparedness) for governments and defence agencies. LEAD ASSET Bucillamine — oral thiol-based compound Bucillamine is an oral, thiol-based drug with more than 30 y
Slide 5: Governments Are the Buyer
MARKET OPPORTUNITY Governments Are the Buyer Medical countermeasures are purchased directly by governments, defence organizations and public-health agencies that want products developed, procured and stockpiled before an emergency — outside typical commercial drug-reimbursement channels. Established
Slide 6: First DRDC Nerve-Agent Data: Positive
AUGUST 2026 · KEY CATALYST First DRDC Nerve-Agent Data: Positive Defence Research and Development Canada (DRDC) compared bucillamine to N-acetylcysteine (NAC) — the established antioxidant comparator — in a recognized animal model of nerve-agent exposure. Bucillamine matched NAC in preserving hippoc
Slide 7: Why Bucillamine
THE SCIENCE Why Bucillamine Scientific rationale Human-use history A thiol-based drug with antioxidant, anti-inflammatory and thiol-donating More than 30 years of clinical use for rheumatoid arthritis in Japan and South properties — potentially relevant where oxidative stress, inflammation and Korea
Slide 8: Bucillamine Across Four Indications
PIPELINE Bucillamine Across Four Indications Nerve-Agent Exposure PRE-CLINICAL DRDC — Suffield Research Centre. Positive initial results; confirmatory studies from Q4-2026. Pandemic Preparedness — Influenza, COVID-19, Emerging Viral Infections PHASE 3 COMPLETED Supported by granted Canadian infectio
Slide 9: Potential Applications Under Evaluation
PIPELINE EXPANSION Potential Applications Under Evaluation Bucillamine alongside established treatments — brain injury, oxidative stress, LEAD Nerve-Agent Exposure respiratory function, response to standard care. Whether nerve-agent findings support research into poisoning from related NEAR-TERM Org
Slide 10: How Value Could Be Created
COMMERCIALIZATION PATHWAYS How Value Could Be Created 01 02 03 04 Co-Development & Procurement & Funded Research International Partnering Licensing Stockpiling Defence, pharma, biotech and Qualified countermeasures may be Regional licences with allied markets Government studies, grants and manufactu
Slide 11: Strategy & Roadmap Forward
STRATEGIC PRIORITIES Strategy & Roadmap Forward 1 Confirm & Prioritize Work with DRDC through confirmatory studies and select the indications worth advancing. 2 Build Government & Regulatory Pathway Establish pathways in Canada, the U.S. and allied nations. 3 Strengthen & Broaden IP Expand patent co
Slide 12: What to Watch Next
MILESTONES What to Watch Next DONE · AUG 2026 Q4 2026 2026–2027 ONGOING ONGOING Positive DRDC results reported; DRDC confirmatory studies continue Selection of priority indications and Discussions with government, Additional patent filings; evaluation biodefence and pandemic- — brain injury, oxidati
Slide 13: Patent Portfolio
INTELLECTUAL PROPERTY Patent Portfolio GRANTED Use of Bucillamine in the Treatment of Infectious Diseases, Including COVID-19 Canadian Patent No. 3,172,170 — expires March 16, 2041. UNDER REVIEW Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare
Slide 14: Leadership & Research Partners
PEOPLE & PARTNERS Leadership & Research Partners LEADERSHIP RESEARCH PARTNERS Michael Frank — Chairman & Chief Executive Officer Carmelo Marrelli — Chief Financial Officer Dr. Kelly McKee, Jr., MD, MPH — Chief Scientific Officer (Consultant) Nerve-agent research at the Suffield Research Centre, Depa
Slide 15: Stock & Capital Snapshot
CAPITAL STRUCTURE Stock & Capital Snapshot SHARE PRICE 52-WEEK HIGH 52-WEEK LOW MARKET CAP C$0.03 C$0.08 C$0.005 ~C$13M COMMON SHARES WARRANTS LISTINGS 435,684,000 63,317,263 RVV · RVVTF · 31R CSE OTCQB Frankfurt Exercise prices range from C$0.05 to C$0.20. REVIVE THERAPEUTICS LTD. | CSE: RVV · OTCQ
Slide 16: Thank You
THANK YOU 82 Richmond Street East, Toronto, ON M5C 1P1 1-888-901-0036 | info@revivethera.com | revivethera.com CSE: RVV OTCQB: RVVTF FRANKFURT: 31R This presentation is for informational purposes only and does not constitute investment advice or an offer to sell securities. Bucillamine is not approv
Revive Therapeutics — Investor Presentation (August 2026) on 6ix